"Success of the microbiome therapeutics market will require a more sophisticated investment environment"
India, May 28 -- Since the company's inception in 2020, what has the journey been like?
Founded in 2020, Genefitletics entered the disease diagnostic space with an audacious vision: What if we could identify abnormalities in cellular energetics before dysfunction manifests, and rewrite the cell's bioelectric code to drive large-scale anatomical goals?
Over the last seven years, Genefitletics has processed over 35 billion data points to map the critical communication network between the human microbiome and mitochondria. Our findings reveal that microbial stress hijacks the energy needed for healthy aging, effectively starving longevity pathways and triggering systemic disease. This journey has yielded six paradigm-shifting scientific in...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.